Addex Therapeutics Ltd.
Addex Therapeutics Ltd. (ADXN) furnished an SEC Form 6-K — earnings release. Exhibit 99.3 PRESS RELEASE Addex Therapeutics Reports 2026 Half-Year Results and Provides Corporate Update Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 28, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical co
Addex Therapeutics (ADXN) will report Q2 2026 results on September 28, 2026. Q1 2026 saw a net loss of CHF 1.71 million, with R&D and admin expenses down. Neurosterix, a spin-out, is advancing NTX-253 for schizophrenia. ADXN raised $2.8 million in August 2026, extending cash runway. Q2 2025 had a net loss of CHF 1.84 million. ADXN stock is at $3.45.
Kalinichev Mikhail (HEAD OF TRANSLATIONAL SCIENCE) sold (to issuer) 306,765 shares of Addex Therapeutics Ltd. (ADXN) on 2026-09-02.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning ADXN (Addex Therapeutics Ltd.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 2 bearish.
Recent ADXN coverage spans insider activity, earnings and technology.
In the last 30 days, ADXN insiders filed 7 SEC Form 4 transactions — no purchases and 7 sales. The most active reporter was Hill Raymond George with 1 filing.
Earnings miss and low cash balance suggest downward pressure on the stock.
Q1 loss deepens and cash runway shortens, but the ATM raise provides liquidity into Q3 2027.
Insider sale may signal lack of confidence, but size is modest for a micro‑cap.
Insider sale may signal lack of confidence, but the amount is modest for a biotech and likely has limited price impact.
Insider sale may signal reduced confidence or simply portfolio rebalancing; limited price impact expected.
AlphAI scores every news story that mentions ADXN with an AI model for sentiment and relevance, and aggregates insider trades from Addex Therapeutics Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Addex Therapeutics Ltd. (ADXN) furnished an SEC Form 6-K — earnings release. Exhibit 99.3 PRESS RELEASE Addex Therapeutics Reports 2026 Half-Year Results and Provides Corporate Update Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 28, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical co
2 min readAddex Therapeutics (ADXN) will report Q2 2026 results on September 28, 2026. Q1 2026 saw a net loss of CHF 1.71 million, with R&D and admin expenses down. Neurosterix, a spin-out, is advancing NTX-253 for schizophrenia. ADXN raised $2.8 million in August 2026, extending cash runway. Q2 2025 had a net loss of CHF 1.84 million. ADXN stock is at $3.45.
2 min readKalinichev Mikhail (HEAD OF TRANSLATIONAL SCIENCE) sold (to issuer) 306,765 shares of Addex Therapeutics Ltd. (ADXN) on 2026-09-02.
1 min readNunn Jason Raleigh sold (to issuer) 219,561 shares of Addex Therapeutics Ltd. (ADXN) on 2026-09-02.
1 min readMills Roger (CHIEF MEDICAL OFFICER) sold (to issuer) 392,837 shares of Addex Therapeutics Ltd. (ADXN) on 2026-09-02.
1 min readManke Isaac sold (to issuer) 219,561 shares of Addex Therapeutics Ltd. (ADXN) on 2026-09-02.
1 min readLawton Vincent Michael sold (to issuer) 2,507,487 shares of Addex Therapeutics Ltd. (ADXN) on 2026-09-02.
1 min readHill Raymond George sold (to issuer) 1,365,532 shares of Addex Therapeutics Ltd. (ADXN) on 2026-09-02.
1 min readDyer Timothy Mark (CHIEF EXECUTIVE OFFICER) sold (to issuer) 16,413,787 shares of Addex Therapeutics Ltd. (ADXN) on 2026-09-02.
1 min readAddex Therapeutics (ADXN) said preclinical rat research published in the International Journal of Neuropsychopharmacology found its mGlu7 NAM ADX71743 increased wakefulness and reduced REM and non-REM sleep, while changing stress-related neurotransmitters across brain regions. The company said results support its mGlu7 program being advanced by Neurosterix. ADXN last traded at $5.79, premarket $6.19.
3 min read